We are live on
!
Find out more
TYCC
Texas Yale Capital Corp Portfolio holdings
AUM
$3.52B
1-Year Est. Return
52.63%
This Fund
S&P 500
This Quarter
Est. Return
+8.54%
1 Year Est. Return
+52.63%
3 Year Est. Return
+137.29%
5 Year Est. Return
+205.78%
10 Year Est. Return
+584.17%
AUM
$3.52B
AUM Growth
+$225M
(+6.8%)
Cap. Flow
+$1.21M
Cap. Flow
% of AUM
0.03%
Top 10 Holdings %
Top 10 Hldgs %
57.87%
Holding
519
New
26
Increased
184
Reduced
95
Closed
19
Top Buys
| 1 |
Boston Scientific
BSX
|
+$1.92M |
| 2 |
Netflix
NFLX
|
+$1.71M |
| 3 |
Liberty Media Series C
FWONK
|
+$1.65M |
| 4 |
Campbell Soup
CPB
|
+$1.35M |
| 5 |
Genuine Parts
GPC
|
+$1.24M |
Top Sells
| 1 |
Jabil
JBL
|
+$23.1M |
| 2 |
Vanguard Growth ETF
VUG
|
+$2.03M |
| 3 |
Apple
AAPL
|
+$1.45M |
| 4 |
HI
Hillenbrand
HI
|
+$1.37M |
| 5 |
Salesforce
CRM
|
+$907K |
Sector Composition
| 1 | Technology | 53.59% |
| 2 | Energy | 7.87% |
| 3 | Financials | 7.7% |
| 4 | Industrials | 4.72% |
| 5 | Consumer Discretionary | 3.21% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
501
Autodesk
ADSK
$45.5B
| – | – |
-750
| Closed | -$222K |
|
502
Alector
ALEC
$163M
| – | – |
-10,000
| Closed | -$15.6K |
|
503
Arcturus Therapeutics
ARCT
$173M
| – | – |
-16,000
| Closed | -$98.1K |
|
504
Ares Management
ARES
$28.1B
| – | – |
-1,478
| Closed | -$239K |
|
|
AUROW
505
Aurora Innovation Warrant
AUROW
$315M
| – | – |
-40,000
| Closed | -$9K |
|
506
AstraZeneca
AZN
$262B
| – | – |
-4,900
| Closed | -$901K |
|
507
Booking.com
BKNG
$139B
| – | – |
-1,100
| Closed | -$236K |
|
508
Editas Medicine
EDIT
$454M
| – | – |
-70,000
| Closed | -$144K |
|
509
Everest Group
EG
$15.1B
| – | – |
-643
| Closed | -$218K |
|
510
Fair Isaac
FICO
$28.4B
| – | – |
-197
| Closed | -$333K |
|
511
Gossamer Bio
GOSS
$81.8M
| – | – |
-10,000
| Closed | -$31K |
|
|
HI
512
DELISTED
Hillenbrand
HI
| – | – |
-43,092
| Closed | -$1.37M |
|
513
Innodata
INOD
$2.01B
| – | – |
-8,440
| Closed | -$430K |
|
514
Intuit
INTU
$79.6B
| – | – |
-430
| Closed | -$285K |
|
515
Kenvue
KVUE
$36.6B
| – | – |
-10,000
| Closed | -$173K |
|
516
Progressive
PGR
$121B
| – | – |
-1,284
| Closed | -$292K |
|
517
Spero Therapeutics
SPRO
$94.4M
| – | – |
-10,000
| Closed | -$23.3K |
|
518
TPG
TPG
$6.99B
| – | – |
-3,900
| Closed | -$249K |
|
|
MIAX
519
Miami International Holdings
MIAX
$4.07B
| – | – |
-5,000
| Closed | -$222K |
|
Similar funds
TH
ACA
AL
BCP
IIM
AAP
TCM
DILIC
Texas Yale Capital Corp's Q1 2026 Portfolio in Review
As of Q1 2026, Texas Yale Capital Corp held 519 positions worth $3.52B, up 6.8% from $3.3B the previous quarter. Its ten largest holdings account for 58% of the portfolio.
Texas Yale Capital Corp's Q1 2026 filing shows 26 new, 184 increased, 95 reduced and 19 closed positions. Its largest new stake was Boston Scientific: 24,049 shares worth $1.51M. The largest sale was Jabil, an estimated $23.1M.
By sector, the portfolio is most concentrated in Technology at 54% of assets, up from 51% a quarter earlier, followed by Energy and Financials.
- Texas Yale Capital Corp's largest Q1 2026 buy was Boston Scientific: 24,049 shares worth $1.51M.
- Texas Yale Capital Corp added most to Netflix in Q1 2026, an estimated $1.71M increase.
- Texas Yale Capital Corp's biggest Q1 2026 reduction was Jabil, cutting an estimated $23.1M.
- Texas Yale Capital Corp fully exited Hillenbrand in Q1 2026, selling an estimated $1.37M.
- Texas Yale Capital Corp's ten largest holdings make up 58% of its $3.52B portfolio in Q1 2026.
- Texas Yale Capital Corp opened 26 new positions and closed 19 in Q1 2026.
- Texas Yale Capital Corp's portfolio value rose 6.8% quarter-over-quarter to $3.52B.
Based on Texas Yale Capital Corp's 13F filing for Q1 2026, filed 4 May 2026.